44
Participants
Start Date
May 18, 2021
Primary Completion Date
August 24, 2022
Study Completion Date
December 6, 2022
STP705
The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
Placebo Saline
Normal Saline
Dermatology, Laser and Vein Specialists of the Carolinas, Charlotte
Center for Clinical and Cosmetic Research, Aventura
Research Institute of the Southeast LLC, West Palm Beach
Tennessee Clinical Research, Nashville
Dermatology Associates of Knoxville, Knoxville
Austin Institute for Clinical Research, Pflugerville
Investigate MD, Scottsdale
Lead Sponsor
Sirnaomics
INDUSTRY